Pathological response in the breast following dual anti-HER2 neoadjuvant chemotherapy for breast cancer
Association of Breast Surgery ePoster Library. McLean R. 05/13/19; 257130; P086
Mr. Ross McLean
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P086
Topic: Non surgical treatments
Background: HER-2 positive breast cancer is increasingly managed with neoadjuvant chemotherapy (NAC), combined with either single or dual anti-HER2 therapy (Trastuzumab±Pertuzumab). Evidence suggests that dual therapy improves the pathological complete response (pCR) rate. This study evaluates the ‘real world' impact of dual therapy in clinical practice. Methods Retrospective data analysis from a large screening institution of all patients undergoing NAC with single or dual anti-HER2 from May 2014-November 2017. Pathological response was assessed according to percentage of residual tumour. Results: Of the sixty-four patients undergoing NAC with anti-HER2 therapy, pCR was achieved in 50% of patients. A higher number of patients achieved pCR in the dual group (single vs. dual,p=0.31), particularly the ER-/HER2+ group (50% vs. 80%). Downstaging of the tumour to facilitate BCS was attempted in 51 patients, and achieved in 38 (75%), with 18 (86%) dual anti-HER2 patients achieving BCS (single vs. dual,p=0.56).Pathological Response Breast to Anti HER-2 Treatment, n(%)pCRpPR: Percentage Residual Tumour<10%10-50%>50%Single Anti HER-215 (40.5)13 (35.1)8 (21.6)1 (2.7)ER-/HER2+8 (50.0)6 (37.5)2 (12.5)0 (0.0)ER+/HER2+7 (33.3)7 (33.3)6 (28.6)1 (4.8)Dual Anti HER-217 (63.0)8 (29.6)2 (7.4)0 (0.0)ER-/HER2+4 (80.0)1 (20.0)0 (0.0)0 (0.0)
Topic: Non surgical treatments
Background: HER-2 positive breast cancer is increasingly managed with neoadjuvant chemotherapy (NAC), combined with either single or dual anti-HER2 therapy (Trastuzumab±Pertuzumab). Evidence suggests that dual therapy improves the pathological complete response (pCR) rate. This study evaluates the ‘real world' impact of dual therapy in clinical practice. Methods Retrospective data analysis from a large screening institution of all patients undergoing NAC with single or dual anti-HER2 from May 2014-November 2017. Pathological response was assessed according to percentage of residual tumour. Results: Of the sixty-four patients undergoing NAC with anti-HER2 therapy, pCR was achieved in 50% of patients. A higher number of patients achieved pCR in the dual group (single vs. dual,p=0.31), particularly the ER-/HER2+ group (50% vs. 80%). Downstaging of the tumour to facilitate BCS was attempted in 51 patients, and achieved in 38 (75%), with 18 (86%) dual anti-HER2 patients achieving BCS (single vs. dual,p=0.56).Pathological Response Breast to Anti HER-2 Treatment, n(%)pCRpPR: Percentage Residual Tumour<10%10-50%>50%Single Anti HER-215 (40.5)13 (35.1)8 (21.6)1 (2.7)ER-/HER2+8 (50.0)6 (37.5)2 (12.5)0 (0.0)ER+/HER2+7 (33.3)7 (33.3)6 (28.6)1 (4.8)Dual Anti HER-217 (63.0)8 (29.6)2 (7.4)0 (0.0)ER-/HER2+4 (80.0)1 (20.0)0 (0.0)0 (0.0)
P086
Topic: Non surgical treatments
Background: HER-2 positive breast cancer is increasingly managed with neoadjuvant chemotherapy (NAC), combined with either single or dual anti-HER2 therapy (Trastuzumab±Pertuzumab). Evidence suggests that dual therapy improves the pathological complete response (pCR) rate. This study evaluates the ‘real world' impact of dual therapy in clinical practice. Methods Retrospective data analysis from a large screening institution of all patients undergoing NAC with single or dual anti-HER2 from May 2014-November 2017. Pathological response was assessed according to percentage of residual tumour. Results: Of the sixty-four patients undergoing NAC with anti-HER2 therapy, pCR was achieved in 50% of patients. A higher number of patients achieved pCR in the dual group (single vs. dual,p=0.31), particularly the ER-/HER2+ group (50% vs. 80%). Downstaging of the tumour to facilitate BCS was attempted in 51 patients, and achieved in 38 (75%), with 18 (86%) dual anti-HER2 patients achieving BCS (single vs. dual,p=0.56).Pathological Response Breast to Anti HER-2 Treatment, n(%)pCRpPR: Percentage Residual Tumour<10%10-50%>50%Single Anti HER-215 (40.5)13 (35.1)8 (21.6)1 (2.7)ER-/HER2+8 (50.0)6 (37.5)2 (12.5)0 (0.0)ER+/HER2+7 (33.3)7 (33.3)6 (28.6)1 (4.8)Dual Anti HER-217 (63.0)8 (29.6)2 (7.4)0 (0.0)ER-/HER2+4 (80.0)1 (20.0)0 (0.0)0 (0.0)
Topic: Non surgical treatments
Background: HER-2 positive breast cancer is increasingly managed with neoadjuvant chemotherapy (NAC), combined with either single or dual anti-HER2 therapy (Trastuzumab±Pertuzumab). Evidence suggests that dual therapy improves the pathological complete response (pCR) rate. This study evaluates the ‘real world' impact of dual therapy in clinical practice. Methods Retrospective data analysis from a large screening institution of all patients undergoing NAC with single or dual anti-HER2 from May 2014-November 2017. Pathological response was assessed according to percentage of residual tumour. Results: Of the sixty-four patients undergoing NAC with anti-HER2 therapy, pCR was achieved in 50% of patients. A higher number of patients achieved pCR in the dual group (single vs. dual,p=0.31), particularly the ER-/HER2+ group (50% vs. 80%). Downstaging of the tumour to facilitate BCS was attempted in 51 patients, and achieved in 38 (75%), with 18 (86%) dual anti-HER2 patients achieving BCS (single vs. dual,p=0.56).Pathological Response Breast to Anti HER-2 Treatment, n(%)pCRpPR: Percentage Residual Tumour<10%10-50%>50%Single Anti HER-215 (40.5)13 (35.1)8 (21.6)1 (2.7)ER-/HER2+8 (50.0)6 (37.5)2 (12.5)0 (0.0)ER+/HER2+7 (33.3)7 (33.3)6 (28.6)1 (4.8)Dual Anti HER-217 (63.0)8 (29.6)2 (7.4)0 (0.0)ER-/HER2+4 (80.0)1 (20.0)0 (0.0)0 (0.0)
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}